Synthetic organic

AZD4877.

AZD4877.

TargetsCXCR2In vitroAZD5069 is a slowly reversible antagonist of CXCR2 with effects of time and temperature evident on the pharmacology and binding kinetics.In vivoIn preclinical models, airway neutrophil recruitment in response to inflammatory

TargetsCXCR2In vitroAZD5069 is a slowly reversible antagonist of CXCR2 with effects of time and temperature evident on the pharmacology and binding kinetics.In vivoIn preclinical models, airway neutrophil recruitment in response to inflammatory

TargetsCXCR2In vitroAZD5069 is a slowly reversible antagonist of CXCR2 with effects of time and temperature evident on the pharmacology and binding kinetics.In vivoIn preclinical models, airway neutrophil recruitment in response to inflammatory

TargetsCXCR2In vitroAZD5069 is a slowly reversible antagonist of CXCR2 with effects of time and temperature evident on the pharmacology and binding kinetics.In vivoIn preclinical models, airway neutrophil recruitment in response to inflammatory

TargetsCXCR2In vitroAZD5069 is a slowly reversible antagonist of CXCR2 with effects of time and temperature evident on the pharmacology and binding kinetics.In vivoIn preclinical models, airway neutrophil recruitment in response to inflammatory

TargetsCXCR2In vitroAZD5069 is a slowly reversible antagonist of CXCR2 with effects of time and temperature evident on the pharmacology and binding kinetics.In vivoIn preclinical models, airway neutrophil recruitment in response to inflammatory

AZD5069.

AZD5069.

AZD5363 potently inhibits all isoforms of Akt(Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM in cell-free assays, similar to P70S6K/PKA and lower activity towards ROCK1/2.

AZD5363 potently inhibits all isoforms of Akt(Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM in cell-free assays, similar to P70S6K/PKA and lower activity towards ROCK1/2.